ES2088778T5 - Destoxificacion genetica de la toxina de la tos ferina. - Google Patents
Destoxificacion genetica de la toxina de la tos ferina.Info
- Publication number
- ES2088778T5 ES2088778T5 ES88311133T ES88311133T ES2088778T5 ES 2088778 T5 ES2088778 T5 ES 2088778T5 ES 88311133 T ES88311133 T ES 88311133T ES 88311133 T ES88311133 T ES 88311133T ES 2088778 T5 ES2088778 T5 ES 2088778T5
- Authority
- ES
- Spain
- Prior art keywords
- toxine
- vaccine
- ferina
- ter
- pertussis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001784 detoxification Methods 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 201000005702 Pertussis Diseases 0.000 abstract 2
- 108010081690 Pertussis Toxin Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229930186900 holotoxin Natural products 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002998 immunogenetic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002703 mutagenesis Methods 0.000 abstract 1
- 231100000350 mutagenesis Toxicity 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE DESCRIBE UN NUEVO METOD PARA LA PREPARACION DE UNA VACUNA SEGURA, EFICAZ E INMUNOGENICA PARA LA PROTECCION CONTRA ENFERMEDAD PERTUSSIS. EL DESARROLLO DE ESTA VACUNA, SE HA IDENTIFICADO LOS SITIOS ESPECIFICOS FUNCIONALES DE LA TOXINA PERTUSSIS, Y UTILIZANDO ESTA INFORMACION, SE HAN PRODUCIDO HOLOTOXINAS DE CUANTAS DEFINIDAS POR MUTAGENESIS DIRECTA DEL GEN DE LA TOXINA. SE DETOXIFICAN UN NUMERO DE ESTAS TOXINAS ANALOGAS, RETIENE EL EPITOPU S1 INMUNODOMINANTE, SON INMUNOGENETICOS Y PROTECTIVOS EN EL TEST DE POTENCIA DE LA VACUNA PERTUSSIS STANDARD EN RATAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878727489A GB8727489D0 (en) | 1987-11-24 | 1987-11-24 | Detoxification of pertussis toxin |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2088778T3 ES2088778T3 (es) | 1996-09-16 |
ES2088778T5 true ES2088778T5 (es) | 2001-09-01 |
Family
ID=10627453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES88311133T Expired - Lifetime ES2088778T5 (es) | 1987-11-24 | 1988-11-24 | Destoxificacion genetica de la toxina de la tos ferina. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5085862A (es) |
EP (2) | EP0322115B2 (es) |
JP (1) | JP2714068B2 (es) |
AT (1) | ATE135043T1 (es) |
CA (1) | CA1341591C (es) |
DE (1) | DE3855072T3 (es) |
ES (1) | ES2088778T5 (es) |
GB (1) | GB8727489D0 (es) |
GR (1) | GR3019238T3 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001976A1 (en) * | 1987-09-04 | 1989-03-09 | Amgen Inc. | Recombinant dna-derived bordetella toxin subunit analogs |
US6713072B1 (en) * | 1987-11-02 | 2004-03-30 | Chiron S.R.L. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
IT1223334B (it) * | 1987-11-02 | 1990-09-19 | Sclavo Spa | Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse |
US5925546A (en) * | 1987-11-02 | 1999-07-20 | Chiron S.P.A. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
US5332583A (en) * | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
AP8900132A0 (en) * | 1988-07-22 | 1991-01-14 | Smithkline Biolog | Bordetella pertussis vaccine |
CA2001774C (en) * | 1988-10-28 | 2001-10-16 | James A. Wells | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US7232671B2 (en) | 1989-02-15 | 2007-06-19 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
DK0396964T3 (da) * | 1989-04-28 | 1995-10-30 | Sclavo Spa | Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner |
US5786189A (en) * | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
ATE143692T1 (de) * | 1989-11-29 | 1996-10-15 | Smithkline Beecham Biolog | Neuer impfstoff |
US6197548B1 (en) | 1990-04-02 | 2001-03-06 | Medeva Pharma Limited | Transformed Pichia expressing the pertactin antigen |
US5643753A (en) | 1990-04-18 | 1997-07-01 | Connaught Laboratories Limited | Use of autologous promoters to express gene products in bordetella |
GB9008746D0 (en) * | 1990-04-18 | 1990-06-13 | Connaught Lab | The use of autologous promoters to express gene products in bordetella |
US5637303A (en) * | 1990-10-25 | 1997-06-10 | Commonwealth Scientific And Industrial Research Organisation | Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination |
IL101692A0 (en) * | 1991-05-03 | 1992-12-30 | Amgen Inc | Recombinant b oligomer of pertussis toxin |
GB9115332D0 (en) * | 1991-07-16 | 1991-08-28 | Connaught Lab | Manipulation of gene copy number in bordetella |
CA2129899C (en) * | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
US5856122A (en) * | 1993-08-24 | 1999-01-05 | University Of Alberta | Modification of pertussis toxin |
ATE275970T1 (de) * | 1993-10-05 | 2004-10-15 | Celltech Pharmaceuticals Ltd | Impfstoffzusammensetzungen |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
EP1233022B1 (en) | 1995-05-04 | 2015-12-09 | Aventis Pasteur Limited | Methods of preparation of components of acellular pertussis vaccines |
EP0912726A4 (en) * | 1996-05-10 | 2001-07-18 | Phylomed Corp | METHODS FOR OXIDIZING BISULFIDE LINKS WITH OZONE |
EP1762246A1 (en) | 1996-07-02 | 2007-03-14 | Sanofi Pasteur Limited | Multivalent DTP-Polio vaccines |
FR2754543B1 (fr) * | 1996-10-11 | 1998-12-31 | Pasteur Institut | Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
DE69829400T2 (de) | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
PT1296715E (pt) | 2000-06-29 | 2012-01-19 | Smithkline Beecham Biolog | Composição vacinal multivalente |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
US7597895B2 (en) * | 2001-02-20 | 2009-10-06 | The Governing Council Of The University Of Toronto | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US7556807B2 (en) | 2001-02-20 | 2009-07-07 | Kane Biotech, Inc. | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
US8299210B2 (en) * | 2003-11-20 | 2012-10-30 | Sanofi Pasteur | Methods for purifying pertussis toxin and peptides useful therefor |
CA2553946C (en) | 2004-02-06 | 2019-02-26 | University Of Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
JP2008507294A (ja) | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
AU2008245696B2 (en) | 2007-04-27 | 2013-11-07 | Pelican Technology Holdings, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
TW201103980A (en) | 2009-07-08 | 2011-02-01 | Abbott Biologicals Bv | Viral vaccine and use thereof |
NZ602958A (en) | 2010-03-30 | 2014-07-25 | Pfenex Inc | High level expression of recombinant toxin proteins |
WO2012118693A1 (en) | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
BR112014004162A2 (pt) | 2011-08-22 | 2018-04-24 | Cangene Corp | anticorpos contra clostridium difficile |
IN2014CN04700A (es) | 2011-12-21 | 2015-09-18 | Bionet Asia Co Ltd | |
WO2013130981A1 (en) | 2012-03-02 | 2013-09-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to clostridium difficile toxins |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
BR112015008040A2 (pt) * | 2012-10-12 | 2017-07-04 | Glaxosmithkline Biologicals Sa | composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina |
CN109776676A (zh) | 2012-11-28 | 2019-05-21 | Cnj控股公司 | 针对艰难梭菌的抗体 |
CN105026413B (zh) | 2013-01-04 | 2020-04-24 | 台湾浩鼎生技股份有限公司 | 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂 |
DK2863943T3 (en) | 2013-03-08 | 2016-11-07 | Janssen Vaccines & Prevention Bv | acellular pertussis vaccines |
KR20160040290A (ko) | 2013-08-05 | 2016-04-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 조합 면역원성 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340373C (en) * | 1986-01-28 | 1999-02-02 | Rino Rappuoli | Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin |
DE3781541T2 (de) * | 1986-12-23 | 1993-05-06 | Univ Leland Stanford Junior | Modifiziertes pertussistoxin. |
WO1989001976A1 (en) * | 1987-09-04 | 1989-03-09 | Amgen Inc. | Recombinant dna-derived bordetella toxin subunit analogs |
IT1223334B (it) * | 1987-11-02 | 1990-09-19 | Sclavo Spa | Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse |
AP8900132A0 (en) * | 1988-07-22 | 1991-01-14 | Smithkline Biolog | Bordetella pertussis vaccine |
-
1987
- 1987-11-24 GB GB878727489A patent/GB8727489D0/en active Pending
-
1988
- 1988-11-23 CA CA005839383A patent/CA1341591C/en active Active
- 1988-11-23 US US07/275,376 patent/US5085862A/en not_active Expired - Lifetime
- 1988-11-24 DE DE3855072T patent/DE3855072T3/de not_active Expired - Lifetime
- 1988-11-24 AT AT88311133T patent/ATE135043T1/de not_active IP Right Cessation
- 1988-11-24 JP JP63297152A patent/JP2714068B2/ja not_active Expired - Lifetime
- 1988-11-24 EP EP88311133A patent/EP0322115B2/en not_active Expired - Lifetime
- 1988-11-24 EP EP95111215A patent/EP0688868A1/en not_active Withdrawn
- 1988-11-24 ES ES88311133T patent/ES2088778T5/es not_active Expired - Lifetime
-
1996
- 1996-03-07 GR GR950403616T patent/GR3019238T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE135043T1 (de) | 1996-03-15 |
ES2088778T3 (es) | 1996-09-16 |
DE3855072T2 (de) | 1996-11-14 |
GR3019238T3 (en) | 1996-06-30 |
US5085862A (en) | 1992-02-04 |
EP0322115B1 (en) | 1996-03-06 |
GB8727489D0 (en) | 1987-12-23 |
EP0322115A2 (en) | 1989-06-28 |
DE3855072D1 (de) | 1996-04-11 |
JPH022383A (ja) | 1990-01-08 |
CA1341591C (en) | 2009-02-17 |
EP0322115A3 (en) | 1989-08-23 |
DE3855072T3 (de) | 2001-08-02 |
EP0322115B2 (en) | 2001-02-28 |
JP2714068B2 (ja) | 1998-02-16 |
EP0688868A1 (en) | 1995-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2088778T5 (es) | Destoxificacion genetica de la toxina de la tos ferina. | |
Johnson | Cancer incidence in an area of radioactive fallout downwind from the Nevada test site | |
ES8802275A1 (es) | Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina. | |
ES2176232T3 (es) | Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter. | |
LV10203B (en) | Skin test and test kit for aids | |
ES2145764T3 (es) | Dispositivo y metodos para poner una parte de un primer espacio de nombres a disposicion como una parte de un segundo espacio de nombres. | |
ES2180758T3 (es) | Vacunas de pertussis acelulares y metodos de preparacion de las mismas. | |
ATE127347T1 (de) | Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis. | |
EP0024956A3 (en) | Genetically attenuated bacterial vaccines, method of preparing them, method of protecting animals and humans against infectious diseases and bacterial strains used in it | |
DE69943401D1 (de) | M. tuberculosis offener Leserahmen Rv2660c und deren Verwendung | |
ZA816555B (en) | Novel benzoxazolinones,substituted in the 6-position by an amino-alcohol chain or amino-ketone chain,their preparation and their use in pharmaceutical preparations | |
Cockayne et al. | Antigenic and structural analysis of Treponema denticola | |
ATE195878T1 (de) | Toxine und toxoide von clostridium difficile als schleimhautadjuvans | |
Bader et al. | Immune response induced by N-lauroylsarcosine extracted outer-membrane proteins of an isolate of Edwardsiella ictaluri in channel catfish | |
Palmer | Expanded ilio-sacral joint in the toad Xenopus laevis | |
Löffler | An early meromictic stage in Lobsigensee (Switzerland) as evidenced by ostracods and Chaoborus: Studies of the late quaternary of Lobsigensee No. 12 | |
Hunter | Protection of the Worker Against Injury and Disease.—II | |
Voelz et al. | Studies on persons exposed to plutonium | |
PT96022A (pt) | Processo para a prparacao de toxina bordetella pertussis geneticamente modificada e de nova vacina contra a tosse convulsa contendo a referida toxina | |
Ginzburg et al. | Study on virulence and toxicity of M. tuberculosis strains sensitive and resistant to antituberculous drugs. | |
Lifson et al. | Use of BCG vaccination | |
Tyroler | Salvadoran Rebels & Government Troops Announce 24-hour Ceasefire During Child Vaccination Campaign | |
JPS5299A (en) | Fire escapes for multistoried building | |
Morgan | Lister Hill: Statesman from the South (Chapel Hill and London: The University of North Carolina Press, Fred W. Morrison Series in Southern Studies, 1987) | |
Lewandowski | Antigenic variation in bordetella pertussis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 322115 Country of ref document: ES |